HOME >> MEDICINE >> NEWS
More protests against abortion pill

Drug-induced abortion is now legal in the US, but there's a snag...

AFTER a ten-year fight, the "abortion pill" RU486 is finally available in the US. But the pill's supporters fear theirs may be a pyrrhic victory, because production of a second pill that has to be taken with RU486 is now under threat.

RU486 (mifepristone) was approved in Britain nine years ago as an alternative to surgical abortions in the first two months of pregnancy. But American anti-abortion campaigners fought bitterly against it. Now that the US Food and Drug Administration has approved mifepristone, attention has turned to misoprostol, a prostaglandin pill originally developed to treat gastric ulcers.

Supporters of RU486 told New Scientist that they fear anti-abortion campaigners will target misoprostol supply because, although it is officially produced to treat stomach ulcers, obstetricians use it to complete the abortion process started by RU486.

The Reverend Flip Benham, national director of Operation Rescue-one of the most powerful anti-abortion groups in the US-says any drug firms involved in pharmaceutical abortion will be targeted by his group. "If you're going to go ahead and make this pill, you better know that Christians in America do not want to buy pharmaceuticals from you."

RU486 blocks the action of the hormone progesterone, causing the lining of the uterus to break down. Taken two days later, misoprostol makes the uterus contract and the cervix dilate, helping to expel the embryo. But now it seems even the company that makes misoprostol is getting the jitters.

For years, obstetricians have used misoprostol to dilate the cervix during labour. But only when the FDA was about to approve its use with the abortion pill-following pressure from RU486 supporters-did the manufacturer, Pharmacia, send out a sternly worded letter warning against misoprostol's use during pregnancy. The drugs company insis
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
24-Oct-2000


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. New study in Nature demonstrates protection against cell death during heart attack
3. Vaccine against childhood pneumonia shows promise
4. Mayo Clinic discovers new pathway against pancreatic cancer
5. Orthodontists must brace against back pain
6. NYUS Duster cautions against FDA approval of race-based pharmaceutical
7. Female sex hormones play a vital role in defense against sexually transmitted diseases
8. New European cancer figures for 2004 major efforts needed against the big four killers
9. New highly active agents against sandfly fever
10. New mosquito control strategy proves successful against dengue fever
11. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: More protests against abortion pill

(Date:5/29/2015)... 29, 2015 Ready to hit the road? ... all drivers to get their vehicles ready. With handicapped vehicles, ... Advanced Driving Systems (ADS) is ready to help drivers get ... for summer road trips. , When planning for the big ... ensure that the trip goes smoothly and they are prepared ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... May 29, 2015 According to a recent ... 10 full-time workers has a substance abuse problem - the ... than 111,500 adults with full-time jobs, revealed that 9.5% of ... previous year. (1) The National Council on Alcoholism and Drug ... year, and an estimated 70% of the 14.8 million illicit ...
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Inspire Nexus, ... created a solution to the question many life coaches ... gain the experience and hours necessary to become a ... pondered this question, but not for long. Inspire Nexus, ... to hire Coaches directly. Coaches who have experience coaching ...
Breaking Medicine News(10 mins):Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
(Date:5/29/2015)... 29, 2015  Eli Lilly and Company (NYSE: ... announced that they have entered into a clinical trial ... AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination ... antiangiogenic cancer medicine. The planned study will assess the ... tumors. The Phase I study is expected ...
(Date:5/29/2015)... prostate surgeon and New York Urologist, Dr. David Samadi ... Fusion-Guided Biopsy for detecting aggressive prostate cancer . ... Lenox Hill Hospital is the only center using the revolutionary ... City . We,ve seen tremendous improvement in detecting and ... an MRI makes for a much more accurate diagnosis, especially ...
(Date:5/28/2015)...  Eli Lilly and Company (NYSE: LLY ) announced ... offer for up to $1.6 billion aggregate principal amount of ... notes who tendered, and did not validly withdraw, their notes ... time, on May 27, 2015 (the early tender ... eligible to receive the total consideration. The total consideration for ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
Cached News: